Journal
CLINICAL CHEMISTRY
Volume 57, Issue 1, Pages 84-91Publisher
AMER ASSOC CLINICAL CHEMISTRY
DOI: 10.1373/clinchem.2010.151845
Keywords
-
Categories
Funding
- Leslie and Susan Gonda (Goldschmied) Foundation (Los Angeles, CA)
- Weil Family Foundation (Los Angeles, CA)
- ABC Foundation (Beverly Hills, CA)
- California Breast Cancer Research Program [16IB-0076]
Ask authors/readers for more resources
BACKGROUND: MicroRNAs (miRs) are a class of small noncoding RNAs whose expression changes have been associated with cancer development and progression. Current techniques to isolate miRs for expression analysis from blood are inefficient. We developed a reverse transcription quantitative real-time PCR (RT-qPCR) assay for direct detection of circulating miRs in serum. We hypothesized that serum concentrations of miR-21, a biomarker increased in breast tumors, would correlate with the presence and extent of breast cancer. METHODS: The RT-qPCR applied directly in serum (RT-qPCR-DS) assay for circulating miR-21 was tested in sera from 102 patients with different stages of breast cancer and 20 healthy female donors. RESULTS: The assay was sensitive for detection of miR-21 in 0.625 mu L of serum from breast cancer patients. For differentiation of samples from patients with locoregional breast cancer from those from healthy donors, the odds ratio was 1.796 and the area under the curve was 0.721. In a multivariate analysis that included standard clinicopathologic prognostic factors, high circulating miR-21 concentrations correlated significantly (P < 0.001) with visceral metastasis. CONCLUSIONS: A novel RT-qPCR-DS can improve the efficiency of miR assessment. Use of this assay to detect circulating miR-21 has diagnostic and prognostic potential in breast cancer. (C) 2010 American Association for Clinical Chemistry
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available